# US 2026/0048140 A1 · Novel copolymer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0048140 A1
- Document ID: US20260048140A1
- Status: Published application
- Kind: A1
- Application number: 19/101,030
- Filed: 2023-08-10
- Published: 2026-02-19
- Earliest claimed: 2022-08-10
- Assignees: Kowa Company, Ltd.
- Applicants: Kowa Company, Ltd.
- Inventors: Kenichi SUZUKI; Nobuhiro FUJIMAKI; Yohei ARAI
- Web page: https://patentgrep.com/patent/US20260048140A1

## CPC

- A61K 47/6931: {the material constituting the nanoparticle being a polymer}
- A61P 35/00: Antineoplastic agents
- A61K 9/5138: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 47/58: obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K 47/6898: {using avidin- or biotin-conjugated antibodies}
- C08F 8/12: Hydrolysis
- C08F 2438/03: Use of a di- or tri-thiocarbonylthio compound, e.g. di- or tri-thioester, di- or tri-thiocarbamate, or a xanthate as chain transfer agent, e.g . Reversible Addition Fragmentation chain Transfer [RAFT] or Macromolecular Design via Interchange of Xanthates [MADIX]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08F: MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS

## Abstract

A copolymer in which a target-affinity molecule is bonded to a copolymer X having structural units of (A), (B), and (C): R1, R2, and R3 are the same or different and are hydrogen or C1-3 alkyl. R4 is C1-3 alkyl. R5 is hydrogen, C1-18 alkyl, 3- to 8-membered cycloalkyl optionally having a substituent, adamantyl, C6-18 aryl optionally having a substituent, or a 5- to 10-membered heteroaryl optionally having a substituent. X1, X2, and X3 are the same or different and are oxygen, sulfur, or N—R7. R6 is hydrogen, a leaving group, or a linker. R7 is hydrogen or C1-3 alkyl. m is a number of 1 to 100, and n is 0 to 3.

## Claims

### Claim 1

A copolymer, comprising:
a copolymer X; and
a target-affinity molecule bonded to the copolymer X,
wherein the copolymer X comprises structural units of formulas (A), (B), and (C),
where, R1, R2, and R3 are the same or different and are a hydrogen atom or a C1-3 alkyl group, R4 is a C1-3 alkyl group, R5 is a hydrogen atom, a C1-18 alkyl group, a 3- to 8-membered cycloalkyl group optionally having a substituent, an adamantyl group, a C6-18 aryl group optionally having a substituent, or a 5- to 10-membered heteroaryl group optionally having a substituent, X1, X2, and X3 are the same or different and are an oxygen atom, a sulfur atom, or N—R7, R6 is a hydrogen atom, a leaving group, or a linker, R7 is a hydrogen atom or a C1-3 alkyl group, m is an integer of 1 to 100, and n is an integer of 0 to 3.

### Claim 2 (depends on 1)

The copolymer according to claim 1, wherein the copolymer X is a copolymer formed by polymerization of three types of monomers of formulas (1) to (3),

### Claim at position 3

3-18. (canceled)

### Claim 19 (depends on 1)

The copolymer according to claim 1, wherein the copolymer has a number average molecular weight of 5,000 to 150,000.

### Claim 20 (depends on 1)

The copolymer according to claim 1, wherein the target-affinity molecule is biotin or a derivative thereof.

### Claim 21 (depends on 1)

The copolymer according to claim 1, wherein the target-affinity molecule is a molecule having a biotin residue of formula (a),
where Y is O or NH.

### Claim 22 (depends on 1)

The copolymer according to claim 1, wherein the target-affinity molecule is at least one of molecules of formulas (8) to (11),

### Claim 23 (depends on 1)

The copolymer according to claim 1, wherein the bond of the target-affinity molecule to the copolymer X is a covalent bond or a non-covalent bond.

### Claim 24 (depends on 1)

A single chain nanoparticle, comprising:
the copolymer of claim 1.

### Claim 25 (depends on 1)

A pharmaceutical composition, comprising:
the copolymer of claim 1.

### Claim 26 (depends on 25)

A pre-targeting method, comprising:
administering the pharmaceutical composition of claim 25.

### Claim 27 (depends on 2)

The copolymer according to claim 2, wherein the copolymer has a number average molecular weight of 5,000 to 150,000.

### Claim 28 (depends on 2)

The copolymer according to claim 2, wherein the target-affinity molecule is biotin or a derivative thereof.

### Claim 29 (depends on 2)

The copolymer according to claim 2, wherein the target-affinity molecule is a molecule having a biotin residue of formula (a),
where Y is O or NH.

### Claim 30 (depends on 2)

The copolymer according to claim 2, wherein the target-affinity molecule is any one of molecules of formulas (8) to (11),

### Claim 31 (depends on 2)

The copolymer according to claim 2, wherein the bond of the target-affinity molecule to the copolymer X is a covalent bond or a non-covalent bond.

### Claim 32 (depends on 2)

A single chain nanoparticle, comprising:
the copolymer of claim 2.

### Claim 33 (depends on 2)

A pharmaceutical composition, comprising:
the copolymer of claim 2.

### Claim 34 (depends on 33)

A pre-targeting method, comprising:
administering the pharmaceutical composition of claim 33.
